Tufts CSDD Study -'Assessing the Financial Impact of Translational Pharmaceutics - A Platform for Accelerating Drug Development'

Learn how results from a recent Tufts CSDD study indicate that Translational Pharmaceutics® reduces development times by >12 months and lower R&D costs by >$100 million per approved new drug.

Go to the profile of Quotient Sciences
Quotient Sciences
Published
Like Comment
Go to the profile of Quotient Sciences

Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
7 Contributions
3 Followers
3 Following